Valuation

INVAInnoviva Inc

StockNasdaqUnited StatesHealth careEU retail investors: available

−0.5% today · −8.9% over a year

10/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 95% of the instruments we score

Quality, Stability: among the best of its peers; priced lower than most peers. No dividend.

Innoviva Inc (INVA) valuation against sector peers: P/E 7.0 (sector median 30.9), P/B 1.2, EV/EBIT 6.1, free-cash-flow yield 13.5%, P/S 3.1.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricINVASector medianvs median
P/E7.030.9 · n=15977% below
P/B1.24.0 · n=30770% below
P/S3.14.1 · n=29925% below
EV/EBIT6.125.6 · n=14676% below
Free-cash-flow yield13.5%1.4% · n=288835% above
Dividend yield0.00%0.00% · n=362—
Return on equity18.0%−2.1% · n=308—
Return on invested capital18.3%0.6% · n=2822,736% above
Gross margin74.5%63.3% · n=20518% above
Net debt / EBITDA—1.27 · n=151—

Value factor: 100 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co48.233.0—1.5%0.6%6/10
JNJJohnson & Johnson42.28.3—3.0%1.9%8/10
ABBVAbbVie50.3—27.73.6%2.9%6/10
MRKMerck149.58.2—4.0%2.3%8/10
UNHUnitedHealth22.43.417.16.4%2.3%10/10
TMOThermo Fisher Scientific37.84.935.72.8%0.3%9/10
AMGNAmgen26.817.523.23.8%2.1%8/10
GILDGilead Sciences—16.1—6.6%1.9%5/10
ABTAbbott40.73.832.93.5%2.8%6/10
PFEPfizer41.31.9—7.1%7.4%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 04 Nov 2026